Nwam LLC Halozyme Therapeutics, Inc. Transaction History

Nwam LLC

$1.12 Billion
Q1 2025

A detailed history of Nwam LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Nwam LLC holds 5,398 shares of HALO stock, worth $264,232. This represents 0.03% of its overall portfolio holdings.

Number of Shares

5,398

Previous 5,390 0.15%

Holding current value

$264,232

Previous $257,000 33.85%

% of portfolio

0.03%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	BUY	$47.74 - $65.16 $381 - $521	8 Added 0.15%	5,398 $344,000
Q4 2024 Feb 04, 2025	SELL	$42.57 - $61.09 $170 - $244	-4 Reduced 0.07%	5,390 $257,000
Q3 2024 Nov 12, 2024	BUY	$51.3 - $64.42 $205 - $257	4 Added 0.07%	5,394 $308,000
Q2 2024 Jul 23, 2024	BUY	$37.81 - $52.4 $151 - $209	4 Added 0.07%	5,390 $282,000
Q1 2024 May 09, 2024	SELL	$33.68 - $41.95 $6,230 - $7,760	-185 Reduced 3.32%	5,386 $219,000
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $5,964 - $7,535	-179 Reduced 3.11%	5,571 $205,000
Q2 2023 Aug 09, 2023	SELL	$30.28 - $38.74 $4,542 - $5,811	-150 Reduced 2.54%	5,750 $207,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $36,603 - $49,191	950 Added 19.19%	5,900 $233,000
Q2 2022 Aug 10, 2022	BUY	$37.35 - $48.3 $184,882 - $239,085	4,950 New	4,950 $229,000
Q1 2022 May 12, 2022	SELL	$31.97 - $41.06 $162,247 - $208,379	-5,075 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$31.82 - $40.75 $161,486 - $206,806	5,075 New	5,075 $204,000

Others Institutions Holding HALO

# of Institutions

595

Shares Held

124M

Call Options Held

320K

Put Options Held

113K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.82B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.

Account